Real-Life Cefiderocol Use in Bone and Joint Infection: A French National Cohort.

ABSTRACT: Background: Cefiderocol (CFD) is a novel siderophore cephalosporin developed for the treatment of infections involving multidrug-resistant (MDR) Gram-negative bacilli (GNB) infections (1-3). For bone and joint infections (BJIs), the use of CFD is currently neither part of its market authorization nor recommended, and has not yet been assessed by large-scale studies. Objectives: To fill the scarcity of data regarding the use of CFD in BJIs, we aimed to describe patients' and infection characteristics along with the outcomes of the infection. Methods: We conducted a retrospective observational multicenter study in 22 French centers from January 2019 to December 2023. Results: From January 2019 to December 2023, 45 patients were included. Patients were mainly males

SUBMITTER: Diarra A 

PROVIDER: S-EPMC12023946 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature